S G Deeks

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Practical issues regarding the use of antiretroviral therapy for HIV infection
    S G Deeks
    University of California, School of Medicine, San Francisco 94110, USA
    West J Med 168:133-9. 1998
  2. ncbi request reprint Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
    S G Deeks
    University of California, San Francisco, AIDS Program San Francisco General Hospital, San Francisco General Hospital, San Francisco, CA 94110, USA
    J Infect Dis 179:1375-81. 1999
  3. ncbi request reprint HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy
    S G Deeks
    University of California, San Francisco and San Francisco General Hospital, 94110, USA
    AIDS 13:F35-43. 1999
  4. ncbi request reprint Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
    S G Deeks
    University of California, San Francisco, and San Francisco General Hospital, USA
    N Engl J Med 344:472-80. 2001
  5. ncbi request reprint Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues
    M L Penn
    Gladstone Institute of Virology and Immunology, University of California San Francisco, San Francisco, CA 94141, USA
    AIDS Res Hum Retroviruses 17:517-23. 2001
  6. ncbi request reprint Sustained CD4 responses after virological failure of protease inhibitor-containing therapy
    S G Deeks
    University of California and San Francisco General Hospital, San Francisco, California, USA
    Antivir Ther 4:7-11. 1999
  7. ncbi request reprint International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance
    S G Deeks
    San Francisco General Hospital, San Francisco, California and University of California, San Francisco, California, USA
    J Acquir Immune Defic Syndr 26:S25-33. 2001
  8. ncbi request reprint Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
    C A Stoddart
    Gladstone Institute of Virology and Immunology, University of California at San Francisco, San Francisco, California, USA
    Nat Med 7:712-8. 2001
  9. ncbi request reprint Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis
    L A Napolitano
    Gladstone Institute of Virology and Immunology, San Francisco General Hospital, and Department of Medicine, University of California at San Francisco, San Francisco, California 94110-9100, USA
    Nat Med 7:73-9. 2001
  10. ncbi request reprint Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
    S G Deeks
    University of California, San Francisco, AIDS Program, San Francisco General Hospital, San Francisco, CA 94110, USA
    J Infect Dis 181:946-53. 2000

Collaborators

Detail Information

Publications17

  1. pmc Practical issues regarding the use of antiretroviral therapy for HIV infection
    S G Deeks
    University of California, School of Medicine, San Francisco 94110, USA
    West J Med 168:133-9. 1998
    ..The antiviral activity and clinical efficacy of each therapeutic class is reviewed, with an emphasis on applying current results to clinical decision making. Finally, recently published treatment guidelines are reviewed...
  2. ncbi request reprint Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
    S G Deeks
    University of California, San Francisco, AIDS Program San Francisco General Hospital, San Francisco General Hospital, San Francisco, CA 94110, USA
    J Infect Dis 179:1375-81. 1999
    ..Phenotypic resistance testing may provide a useful tool for selecting more effective salvage regimens...
  3. ncbi request reprint HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy
    S G Deeks
    University of California, San Francisco and San Francisco General Hospital, 94110, USA
    AIDS 13:F35-43. 1999
    ..To determine the HIV RNA and CD4 cell response to both initial and salvage therapy with protease inhibitor-based therapy, and to examine the relationship between the virological response and pre-therapy characteristics...
  4. ncbi request reprint Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
    S G Deeks
    University of California, San Francisco, and San Francisco General Hospital, USA
    N Engl J Med 344:472-80. 2001
    ..In many patients with human immunodeficiency virus (HIV) infection, therapy with potent antiretroviral drugs does not result in complete suppression of HIV replication. The effect of cessation of therapy in these patients is unknown...
  5. ncbi request reprint Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues
    M L Penn
    Gladstone Institute of Virology and Immunology, University of California San Francisco, San Francisco, CA 94141, USA
    AIDS Res Hum Retroviruses 17:517-23. 2001
    ....
  6. ncbi request reprint Sustained CD4 responses after virological failure of protease inhibitor-containing therapy
    S G Deeks
    University of California and San Francisco General Hospital, San Francisco, California, USA
    Antivir Ther 4:7-11. 1999
    ..Observational clinical data of patients receiving protease inhibitor-based therapy who had a sustained CD4 cell count even with incomplete viral suppression will be presented, as well as possible mechanisms and clinical implications...
  7. ncbi request reprint International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance
    S G Deeks
    San Francisco General Hospital, San Francisco, California and University of California, San Francisco, California, USA
    J Acquir Immune Defic Syndr 26:S25-33. 2001
    ..This article describes the scientific literature establishing the efficacy and limitations of NNRTI therapy and attempts to define a role for this class of drug in the long-term treatment of HIV-1 disease...
  8. ncbi request reprint Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
    C A Stoddart
    Gladstone Institute of Virology and Immunology, University of California at San Francisco, San Francisco, California, USA
    Nat Med 7:712-8. 2001
    ..We propose that the inability of PI-resistant HIV-1 to replicate efficiently in thymus contributes to the preservation of CD4+ T-cell counts in patients showing virologic rebound on PI therapy...
  9. ncbi request reprint Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis
    L A Napolitano
    Gladstone Institute of Virology and Immunology, San Francisco General Hospital, and Department of Medicine, University of California at San Francisco, San Francisco, California 94110-9100, USA
    Nat Med 7:73-9. 2001
    ..We propose that IL-7 production increases as part of a homeostatic response to T-cell depletion...
  10. ncbi request reprint Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
    S G Deeks
    University of California, San Francisco, AIDS Program, San Francisco General Hospital, San Francisco, CA 94110, USA
    J Infect Dis 181:946-53. 2000
    ..These observations suggest that transient or partial declines in plasma HIV RNA levels can have sustained effects on CD4+ T cell levels...
  11. ncbi request reprint Determinants of virological response to antiretroviral therapy: implications for long-term strategies
    S G Deeks
    Department of Medicine, University of California San Francisco, San Francisco, CA 94110, USA
    Clin Infect Dis 30:S177-84. 2000
    ..Unfortunately, almost any factor (drug, host, or viral) that leads to virological failure of an initial combination regimen is likely to persist-and perhaps become more challenging-once a salvage regimen is initiated...
  12. ncbi request reprint Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate
    S G Deeks
    San Francisco General Hospital AIDS Program, University of California, San Francisco, California 94110, USA
    J Acquir Immune Defic Syndr 28:336-9. 2001
    ..05); however, the difference between the tenofovir and tenofovir plus hydroxyurea groups was not significant ( p =.90). We conclude that hydroxyurea does not significantly enhance the antiviral activity of low-dose tenofovir...
  13. pmc Variations in the heme oxygenase-1 microsatellite polymorphism are associated with plasma CD14 and viral load in HIV-infected African-Americans
    L Seu
    Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94110, USA
    Genes Immun 13:258-67. 2012
    ..04). These data demonstrate that the HO-1 GT(n) microsatellite polymorphism is associated with higher levels of HO-1 expression and that this pathway may have important effects on the association between inflammation and HIV replication...
  14. ncbi request reprint Protease inhibitors as immunomodulatory drugs for HIV infection
    S G Deeks
    University of California, San Francisco, California, USA
    Clin Pharmacol Ther 82:248-50. 2007
    ..When used in combination, these drugs can lead to durable and perhaps indefinite suppression of viral replication...
  15. pmc Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients
    H Lim
    Department of Medicine, University of California and San Francisco General Hospital, CA, USA
    Clin Exp Immunol 169:182-9. 2012
    ..Defects in functions of T cells from middle-aged HIV-infected men are partially attributable to CD4 T lymphocytopenia and are corrected by lenalidomide...
  16. pmc Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol
    A C Karlsson
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, California 94141, USA
    J Virol 81:11543-8. 2007
    ..The consequences of dual pressures from treatment and CTL need to be considered in monitoring of drug therapy...
  17. pmc Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study
    J C Probasco
    Department of Neurology, University of California San Francisco, CA, USA
    Neurology 71:521-4. 2008
    ..Based on the potential immunomodulatory and antiviral properties of HMG-CoA reductase inhibitors (statins), we examined the effect of atorvastatin on CSF HIV-1 infection and associated CSF abnormalities in a small pilot study...